Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Tolerability of Z-100 in Patients With Early HIV Infection
This study has been terminated.
Study NCT00016692   Information provided by Zeria Pharmaceutical
First Received: May 24, 2001   Last Updated: April 26, 2006   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infections
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Communicable Diseases
Infection
More general conditions related to this trial
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
Z-100
Additional drug interventions recognized in this trial
Specific substance maruyama
More general drug interventions related to this trial
Adjuvants, Immunologic
Antineoplastic Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Zeria Pharmaceutical


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services